LOGIN  |  REGISTER
Terns Pharmaceuticals
Assertio

Molina Healthcare Announces Third Quarter 2024 Earnings Release and Conference Call Dates and Investor Day Meeting

September 09, 2024 | Last Trade: US$188.44 9.29 5.19

LONG BEACH, Calif. / Sep 09, 2024 / Business Wire / Molina Healthcare, Inc. (NYSE: MOH) (“Molina” or the “Company”) today announced it will issue its earnings release for the third quarter ending September 30, 2024, after the market closes on Wednesday, October 23, 2024, and will host a conference call and webcast to discuss the earnings release on Thursday, October 24, 2024, at 8:00 a.m. Eastern Time. To access this interactive teleconference, dial (877) 883-0383 and enter the confirmation number, 7014206. A telephonic replay of the conference call will be available through Thursday, October 31, 2024, by dialing (877) 344-7529 and entering the confirmation number, 5232318.

A live broadcast of Molina Healthcare’s conference call will be available on the Company’s investor relations website, investors.molinahealthcare.com. A 30-day online replay will be available shortly following the conclusion of the live broadcast.

2024 Investor Day

The Company also announced it will host its 2024 Investor Day meeting on Friday, November 8, 2024, in New York City. The publicly webcast event will begin at 9:30 a.m. Eastern Time.

In-person attendance is by invitation only. All others are invited to register for the event on the Company’s investor relations website at investors.molinahealthcare.com, or directly via the following link: Molina Investor Day Meeting 2024. A 30-day online replay of the Investor Day meeting will be available shortly following the conclusion of the live webcast.

About Molina Healthcare

Molina Healthcare, Inc., a FORTUNE 500 company, provides managed healthcare services under the Medicaid and Medicare programs and through the state insurance marketplaces. For more information about Molina Healthcare, please visit MolinaHealthcare.com.

Astria Therapeutics

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page